"EVALUATION OF THYROID STATUS IN NEWLY DIAGNOSED TREATMENT NAIVE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME"
Main Article Content
Keywords
Polycystic ovarian syndrome, Thyroid function, Autoimmune thyroid disease, Insulin resistance, Dyslipidemia
Abstract
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder among women of reproductive age, with significant reproductive and metabolic implications, including links to insulin resistance, dyslipidemia, and cardiovascular risks. Recent studies indicate an association between PCOS and thyroid dysfunction, particularly autoimmune thyroid disease, highlighting the need for a better understanding of this relationship to improve patient management, especially in high-prevalence regions like Kashmir. This study aimed to evaluate thyroid function status in newly diagnosed PCOS patients and assess the prevalence of autoimmune thyroid disease in this population. Conducted as a cross-sectional study, it included 90 newly diagnosed, treatment-naive PCOS patients aged 20–35 years with BMI 18.5–30 kg/m², along with 90 age and BMI-matched controls. PCOS diagnosis was based on the Rotterdam criteria, and thyroid function tests (T3, T4, TSH, anti-TPO antibodies), lipid profile, and insulin resistance markers (fasting insulin, HOMA-IR) were measured. Statistical analysis was conducted with significance set at p < 0.05. The results revealed significant differences between PCOS cases and controls in waist circumference, systolic and diastolic blood pressure, T3, T4, TSH, anti-TPO levels, and lipid profile components (TG, HDL, LDL). Insulin resistance markers (fasting insulin, HOMA-IR) were also markedly higher in the PCOS group. The study highlights a strong association between PCOS and thyroid dysfunction, particularly autoimmune thyroid disease, as well as insulin resistance and dyslipidemia, suggesting that routine screening for thyroid and metabolic abnormalities in PCOS patients may be beneficial for early intervention and improved long-term outcomes.
References
2. Meier RK. Polycystic Ovary Syndrome. Nurs Clin N Am. 2018;53:407–20.
3. Diamanti-Kandarakis E, Dunaif A. Insulin Resistance and Polycystic Ovarian Syndrome. Endocr Rev. 2012;33(6):981–1030.
4. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810–2.
5. Bernier D. Polycystic Ovary Syndrome: Pathogenesis, health consequences, and treatment of PCOS in relation to insulin resistance [Internet]. 2012. Honors Theses and Capstones;3. Available from: https://scholars.unh.edu/honors/3
6. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467–520.
7. Kabel AM. Polycystic ovarian syndrome: insights into pathogenesis, diagnosis, prognosis, pharmacological and nonpharmacological treatment. Pharm Bioprocess. 2016;4(1):7–12.
8. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013; 6:1–13. doi: 10.2147/CLEP.S37559
9. Mallick MS, Khatun S. Study on correlation between endocrine and metabolic parameters in polycystic ovary syndrome and thyroid-stimulating hormone: should normal thyroid-stimulating hormone level be redefined. Int J Sci Study. 2018;6(3).
10. Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–71.
11. Ganie MA, Rashid A, Sahu D, Nisar S, Wani IA, Khan J. Prevalence of polycystic ovary syndrome (PCOS) among reproductive age women from Kashmir valley: A cross-sectional study. Int J Gynaecol Obstet. 2020;149(2):231–6.
12. Yildiz BO, Sevtap KA, Muammer D, et al. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril. 2010;93(6):1864–9.
13. Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi Med J. 2007;28(7):1039–43.
14. Ganie MA, Marwaha RK, Aggarwal R, Singh S. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. Eur J Endocrinol. 2010;162:1117–22.
15. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
16. Maraka S, Singh Ospina NM, Mastorakos G, et al. Subclinical hypothyroidism in women planning conception and during pregnancy: who should be treated and how? J Endocr Soc. 2018;2:533–46.
17. Dahlgren E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril. 1994;61(3):455–60.
18. Kamrul-Hasan A, Aalpona FTZ, Selim S. Impact of Subclinical Hypothyroidism on Reproductive and Metabolic Parameters in Polycystic Ovary Syndrome - A Cross-sectional Study from Bangladesh. Eur Endocrinol. 2020;16(2):156–60.
19. Munaver SA, Zahra F, Azhar F, Siddiqui QA. Association of LH/FSH ratio with thyroid stimulating hormone and prolactin levels in women with polycystic ovarian syndrome in Pakistan. J Dow Univ Health Sci. 2022. doi: 10.36570/jduhs.2022.
20. Fatema K, Das TR, Kazal RK, Mahamood S, Pervin HH, Noor F, Chakma B. Prevalence and characteristics of polycystic ovarian syndrome in women attending in outpatient department of obstetrics and gynecology of Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Int J Reprod Contracept Obstet Gynecol. 2021;10(3):830–6.
21. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta analysis. Hum Reprod Update. 2012;18:618–37.
22. Aina DA. Establishing the hormonal relationship between polycystic ovary syndrome and hypothyroidism: a literature review. Med Stud Res J. 2020;7:1–7.
23. Sinha U, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK. Thyroid disorders in polycystic ovarian syndrome subjects: a tertiary hospital-based cross-sectional study from Eastern India. Indian J Endocrinol Metab. 2013;17(2):304. doi: 10.4103/2230-8210.109714
24. Novais JDSM, Benetti-Pinto CL, Garmes HM, Menezes Jales R, Juliato CRT. Polycystic ovary syndrome and chronic autoimmune thyroiditis. Gynecol Endocrinol. 2015;31(1):48–51.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Humairah Shafi
Senior Resident, Department of Physiology, Government Medical College, Srinagar, J & K, India.
Dr Samia Mearaj
Post Graduate Scholar, Department of Physiology, Government Medical College, Srinagar, J & K, India
Dr Khalid Ahmad Bhat
Post Graduate Scholar, Department of Physiology, Government Medical College, Srinagar, J & K, India
Dr Shabir Ud din Lone
Professor, Department of Physiology, Government Medical College, Srinagar, J & K, India.
Dr. Nazir Ahmad Pala
Associate Professor (Endocrinology), Department of Medicine, Government Medical College, Srinagar, J & K, India.
Dr. Sabhiya Majid
Professor and Head, Department of Biochemistry, Government Medical College, Srinagar, J & K, India.
Dr. Sheikh Imran Sayeed
Professor and HOD, Department of Physiology, Government Medical College, Srinagar, India.